10463-20-4

Basic information

• Product Name: 4-HYDROXY-3-NITROPHENYLACETIC ACID
• Synonyms: 4-Hydroxy-3-nitrobenzeneacetic acid;4-Hydroxy-3-nitrophenylacetic acid,99%;Benzeneacetic acid, 4-hydroxy-3-nitro-;TIMTEC-BB SBB007785;2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID;4-HYDROXY-3-NITROPHENYLACETIC ACID;3-NITRO-4-HYDROXYPHENYLACETIC ACID;4-Hydroxy-3-nitrophenylacetic acid 98%
• CAS NO: 10463-20-4
• Molecular Formula: C₈H₇NO₅
• Molecular Weight: 197.14
• EINECS: 233-948-0
• Product Categories: Carboxylic Acids;Phenyls & Phenyl-Het;Carboxylic Acids;Phenyls & Phenyl-Het;C8;Carbonyl Compounds;Aromatics;Metabolites & Impurities;Aromatics, Metabolites & Impurities;Aromatic Phenylacetic Acids and Derivatives
• Mol File: 10463-20-4.mol
• Article Data: 23

Chemical Properties

• Melting Point: 146-148 °C(lit.)
• Boiling Point: 334.23°C (rough estimate)
• Flash Point: 179 °C
• Appearance: yellow/crystalline
• Density: 1.5023 (rough estimate)
• Vapor Pressure: 5.38E-07mmHg at 25°C
• Refractive Index: 1.5700 (estimate)
• Storage Temp.: −20°C
• Solubility: ethanol: soluble5%, clear, yellow to orange
• PKA: 4.25±0.10(Predicted)
• BRN: 2696044
• CAS DataBase Reference: 4-HYDROXY-3-NITROPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-3-NITROPHENYLACETIC ACID(10463-20-4)
• EPA Substance Registry System: 4-HYDROXY-3-NITROPHENYLACETIC ACID(10463-20-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• TSCA: T
• HazardClass: IRRITANT
• Hazardous Substances Data: 10463-20-4(Hazardous Substances Data)

Usage

Chemical Properties

yellow crystalline powder

Uses

Different sources of media describe the Uses of 10463-20-4 differently. You can refer to the following data:
1. A metabolite of Nitrotyrosine (N597000), which is excreted in the urine.
2. 4-Hydroxy-3-nitrophenylacetic acid was used in the synthesis of 4-hydroxy-3-nitrophenylacetyl caproic acid.

Synthesis Reference(s)

Journal of Medicinal Chemistry, 30, p. 1166, 1987 DOI: 10.1021/jm00390a009

General Description

4-Hydroxy-3-nitrophenylacetic acid enhances the ice-nucleation activity of Xanthomonas campestris.

InChI:InChI=1/C8H7NO5/c10-7-2-1-5(4-8(11)12)3-6(7)9(13)14/h1-3,10H,4H2,(H,11,12)/p-2

Upstream product

• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 10463-21-5 3-nitro-4-hydroxyphenylacetyl chloride 
• 185104-75-0 N-[2-(3,4-Bis-benzyloxy-phenyl)-ethyl]-2-(4-hydroxy-3-nitro-phenyl)-acetamide 
• 518977-84-9 t-butyl 4-hydroxy-3-nitrobenzene-acetate 
• 147498-82-6 N-{3-(3,4-dimethylphenyl)propyl}-4-hydroxy-3-nitrophenylacetamide 
• 1033605-95-6 N-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-2-(4-hydroxy-3-nitrophenyl)acetamide 
• 78587-72-1 methyl (3-amino-4-hydroxyphenyl)acetate 
• 853929-59-6 (2-{4-[(E)-3-(4-bromophenyl)acryloylamino]-3-fluorophenyl}benzooxazol-5-yl) acetic acid 

Relevant articles and documents

Highly efficient and stable catalyst for peroxynitrite decomposition

The new cobalt substituted-polyoxometalate K7[CoAlW11O39]·15H2O and the simple CoCl2·6H2O salt are efficient catalysts for peroxynitrite decomposition. These compounds also catalyze the oxidation of ascorbic acid and the nitration of phenol by peroxynitrite.

RAPID DECOMPOSITION OF PEROXYNITRITE BY MANGANESE PORPHYRIN-ANTIOXIDANT REDOX COUPLES

-

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

Targeted probes of cellular physiology

Biosensor comprising an activatable acceptor fluorogen linked via a linker to a donor which transfers energy to the fluorogen on detecting an analyte wherein the fluorogen component reacts and a 100 fold increase in intensity results when the fluorogen interacts non-covalently with an activator e.g. fluorogen activator peptide.

NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I) wherein R1, R2 are independently selected from hydrogen and Cu alkyl; R3 is hydrogen or C1-4 alkyl group which is unsubstituted or substituted by phenyl, pyridyl, or amino optionally substituted by C1-4 alkyl; R4 is hydrogen; R5 is C1-4 alkyl group; R6 is selected from monocyclic aryl, which is a six membered ring unsubstituted or substituted by one or more identical or different groups selected from C1-4 alkyl groups, C1-4 alkoxy, halogenated C1-4 alkyl, phenyl, phenoxy, halogen, nitro; or mono- or bi- or tricyclic heteroaryl group consisting of five or six membered ring(s) having 1 to 3 identical or different hetero atoms selected from nitrogen, oxygen and sulfur, in which at least one of the rings is aromatic, and wherein the rings are optionally substituted by one or more identical or different groups selected from C1-4 alkyl, mono-, di-, tri- halogenated C1-4 alkyl, C1-4 alkoxy, hydroxyl, halogen; their positional isomers, racemates and enantiomers, diastereoisomers, and addition salts with a pharmaceutically acceptable acid, solvates, their complexes, adducts and prodrugs, having a selective dual action on the central GABAergic system, to a process for their preparation and to pharmaceutical compositions containing them.